(USNA) USANA Health Sciences - Ratings and Ratios
Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US90328M1071
USNA: Nutritional Supplements, Skincare Products, Food Products, Business Tools
USANA Health Sciences Inc (NYSE:USNA) is a leading developer, manufacturer, and distributor of premium nutritional supplements, personal care products, and skincare solutions, operating globally across the Asia Pacific, the Americas, and Europe. The companys product portfolio is diversified across two primary business segments: Direct Selling and Hiya Direct-To-Consumer, catering to a wide range of customer needs.
The companys product offerings include a broad spectrum of nutritional supplements, such as USANA nutritional optimizers, Essentials/CellSentials, and food products designed for healthy weight management, digestive health, and energy and hydration. Additionally, USANA provides Celavive, a comprehensive skincare regimen tailored to various skin types and ethnicities, as well as other products and tools aimed at supporting associates in building their businesses and marketing efforts.
USANAs distribution strategy encompasses multiple channels, including retail customers, subscription models, direct selling, and online sales, allowing the company to effectively reach and serve its diverse customer base. The company has also established strategic research collaborations with reputable institutions, such as Beijing University of Chinese Medicine and the National Sports Training Bureau, to drive innovation and stay at the forefront of the industry.
From a technical analysis perspective, USANAs stock price has been trending below its 200-day Simple Moving Average (SMA), indicating a potential downtrend. However, the stocks current price is above its 20-day and 50-day SMAs, suggesting a short-term uptrend. The Average True Range (ATR) indicates a moderate level of volatility. Considering the
Fundamentally, USANAs market capitalization stands at $528.83M USD, with a Price-to-Earnings (P/E) ratio of 15.41 and a Forward P/E of 10.68, indicating a relatively reasonable valuation. The companys Return on Equity (RoE) is 6.63%, suggesting a moderate level of profitability. By analyzing the
Based on the analysis of both
Additional Sources for USNA Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
USNA Stock Overview
Market Cap in USD | 529m |
Sector | Consumer Defensive |
Industry | Packaged Foods |
GiC Sub-Industry | Personal Care Products |
IPO / Inception | 1996-07-25 |
USNA Stock Ratings
Growth Rating | -87.4 |
Fundamental | 0.75 |
Dividend Rating | 0.0 |
Rel. Strength | -41.4 |
Analysts | 3/5 |
Fair Price Momentum | 21.03 USD |
Fair Price DCF | 56.88 USD |
USNA Dividends
No Dividends PaidUSNA Growth Ratios
Growth Correlation 3m | -66.3% |
Growth Correlation 12m | -94.2% |
Growth Correlation 5y | -88.6% |
CAGR 5y | -19.43% |
CAGR/Max DD 5y | -0.25 |
Sharpe Ratio 12m | -0.11 |
Alpha | -43.61 |
Beta | 0.655 |
Volatility | 33.63% |
Current Volume | 230.2k |
Average Volume 20d | 227.8k |
As of May 09, 2025, the stock is trading at USD 29.18 with a total of 230,210 shares traded.
Over the past week, the price has changed by +4.07%, over one month by +20.53%, over three months by -5.96% and over the past year by -35.18%.
Neither. Based on ValueRay Fundamental Analyses, USANA Health Sciences is currently (May 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 0.75 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of USNA as of May 2025 is 21.03. This means that USNA is currently overvalued and has a potential downside of -27.93%.
USANA Health Sciences has received a consensus analysts rating of 3.00. Therefor, it is recommend to hold USNA.
- Strong Buy: 0
- Buy: 0
- Hold: 1
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, USNA USANA Health Sciences will be worth about 23.2 in May 2026. The stock is currently trading at 29.18. This means that the stock has a potential downside of -20.36%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 61 | 109% |
Analysts Target Price | 51.5 | 76.5% |
ValueRay Target Price | 23.2 | -20.4% |